Strikingly, neurofilament light chain, a marker of axonal injury [20], can serve as a potential biomarker for CSF1R-related leukoencephalopathy as higher levels are evident in both the serum and cerebrospinal fluid of these patients compared to in MS patients [21]. Here, CSF1R is linked to myeloid sarcoma.